Oncology Medical News

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective study.
BMC Cancer, 09/30/09

Lievre A et al. – Bevacizumab combined with FOLFOX or FOLFIRI may have the possibility to be active in chemorefractory and selected mCRC patients who did not receive it previously

Methods

31 treated patients in a retrospective study
All patients progressed under a chemotherapy with fluoropyrimidine plus irinotecan and/or oxaliplatin and received bevacizumab (5mg/kg) in combination with FOLFIRI or simplified FOLFOX4 every 14 days

Results

Ten patients (32.2%) had an objective response (1 CR, 9 PR) and 12 (38.8%) were stabilized
The response and disease control rates were 45.4% and 100% when bevacizumab was administered in 2nd or 3rd line and 25% and 55% in 4th or later line respectively
Among the patients who had previously received the same chemotherapy than that associated with bevacizumab (n=28) the overall response rate was 35.7% and 39.3% were stabilized
Median progression free survival (PFS) and overall survival (OS) were of 9.7 and 18.4 months respectively

<< Previous
High factor VIII levels independently predict venous...

Next >>
Metabolic syndrome components and colorectal adenoma in the CLUE...